HeiLongJiang ZBD Pharmaceutical Co., Ltd. is a company that specializes in the research, development, production, and sale of traditional Chinese medicine. In addition to this, the company also trades in drug and Chinese herbal medicine. The business areas of the company include both industrial and commercial sectors. The products offered by the company include Chinese medicine preparations, biological agents, and chemical agents. The company was established by Tong Hua Fang on October 28, 1996 and is based in Harbin, China.

Tags

Neoplasms

Respiratory Diseases

Infectious Diseases

Small molecule drug

Herbal medicine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2
Infectious Diseases	2
Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	3
Herbal medicine	2

Top 5 Target	Count

neuraminidase	1
FGFRs x VEGFR	1
Akt(Proto-oncogene proteins c-akt)	1

Drugs associated with HeiLongJiang ZBD Pharmaceutical Co., Ltd.

FuFangQinlan

Target-

Mechanism-

Active Org.

HeiLongJiang ZBD Pharmaceutical Co., Ltd.

Originator Org.

HeiLongJiang ZBD Pharmaceutical Co., Ltd.

Active Indication

Common Cold [+2]

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date30 Nov 2002

XueShuanTong Capsule

Target-

Mechanism-

Active Org.

Haerbin Zhenbao Pharmacy Co. Ltd.

Originator Org.-

Active Indication

Angina Pectoris [+2]

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.-

First Approval Date-

HNC-042

Target

neuraminidase

Mechanism

neuraminidase inhibitors

Active Org.

HeiLongJiang ZBD Pharmaceutical Co., Ltd. [+1]

Originator Org.

Guangzhou Koncen Bioscience Co., Ltd.

Active Indication

Influenza, Human

Inactive Indication-

Drug Highest PhasePhase 2

First Approval Ctry. / Loc.-

First Approval Date-

Clinical Trials associated with HeiLongJiang ZBD Pharmaceutical Co., Ltd.

CTR20233791

/ CompletedNot Applicable

一项单中心、随机、开放、单剂量、两周期、交叉试验评价两种布瑞哌唑片（规格：2mg）空腹和餐后状态下在中国健康人群中的生物等效性

[Translation] A single-center, randomized, open-label, single-dose, two-period, crossover study to evaluate the bioequivalence of two brexpiprazole tablets (strength: 2 mg) in fasting and fed states in healthy Chinese subjects

主要目的：以哈尔滨珍宝制药有限公司生产的布瑞哌唑片（规格：2mg）作为受试制剂，以大塚製薬株式会社持证的布瑞哌唑片（商品名：Rexulti®，规格：2mg）为参比制剂，评估空腹及餐后状态下两种制剂的生物等效性。次要目的：评价受试制剂布瑞哌唑片（规格：2mg）和参比制剂布瑞哌唑片（商品名：Rexulti®，规格：2mg）在健康受试者中的安全性。

[Translation]

main purpose: The test preparation was bripipiprazole tablets (specification: 2 mg) produced by Harbin Zhenbao Pharmaceutical Co., Ltd., and bripipiprazole tablets (trade name: Rexulti®, specification: 2 mg) certified by Otsuka Manufacturing Co., Ltd. Reference preparation to evaluate the bioequivalence of two preparations in fasting and postprandial states. Secondary purpose: To evaluate the safety of the test preparation Bripipiprazole Tablets (specification: 2 mg) and the reference preparation Bripipiprazole Tablets (trade name: Rexulti®, specification: 2 mg) in healthy subjects.

Start Date26 Dec 2023

Sponsor / Collaborator

Haerbin Zhenbao Pharmacy Co. Ltd.

CTR20233628

/ CompletedNot Applicable

盐酸莫西沙星片在中国健康受试者中进行的单中心、随机、开放、单次（空腹/餐后）口服给药、两制剂、两序列、两周期、交叉的人体生物等效性试验

[Translation] A single-center, randomized, open-label, single-dose (fasting/postprandial) oral bioequivalence study of moxifloxacin hydrochloride tablets in healthy Chinese subjects: two-formulation, two-sequence, two-period, crossover

主要目的：观察中国健康受试者在空腹/餐后状态下单次口服受试制剂盐酸莫西沙星片（规格：0.4g；生产企业：哈尔滨珍宝制药有限公司）和参比制剂盐酸莫西沙星片（商品名：Avelox®（拜复乐）；规格：0.4g；生产企业：Bayer HealthCare Manufacturing.S.r.l.；持证商：Bayer Vital GmbH）后的药代动力学特征，评价空腹/餐后状态下两种制剂的生物等效性。次要目的：观察受试制剂盐酸莫西沙星片和参比制剂盐酸莫西沙星片（Avelox®）在中国健康受试者中的安全性。

[Translation]

Primary objective: To observe the pharmacokinetic characteristics of the test preparation Moxifloxacin Hydrochloride Tablets (Specification: 0.4g; Manufacturer: Harbin Zhenbao Pharmaceutical Co., Ltd.) and the reference preparation Moxifloxacin Hydrochloride Tablets (Trade name: Avelox®; Specification: 0.4g; Manufacturer: Bayer HealthCare Manufacturing. S.r.l.; Licensee: Bayer Vital GmbH) after a single oral administration in the fasting/postprandial state in healthy Chinese subjects, and to evaluate the bioequivalence of the two preparations in the fasting/postprandial state. Secondary objective: To observe the safety of the test preparation Moxifloxacin Hydrochloride Tablets and the reference preparation Moxifloxacin Hydrochloride Tablets (Avelox®) in healthy Chinese subjects.

Start Date12 Dec 2023

Sponsor / Collaborator

Haerbin Zhenbao Pharmacy Co. Ltd.

CTR20230411

/ CompletedNot Applicable

一项单中心、随机、开放、单剂量、两周期、两序列、交叉试验评价两种富马酸比索洛尔片（规格：5 mg）空腹和餐后状态下在中国健康人群中的生物等效性

[Translation] A single-center, randomized, open-label, single-dose, two-period, two-sequence, crossover study to evaluate the bioequivalence of two bisoprolol fumarate tablets (strength: 5 mg) in the fasting and fed state in healthy Chinese subjects

以哈尔滨珍宝制药有限公司生产的富马酸比索洛尔片（规格：5 mg）作为受试制剂，以Merck Serono GmbH持证的富马酸比索洛尔片（商品名：康忻®；规格：5 mg）为参比制剂，评估受试制剂和参比制剂在空腹及餐后条件下给药时的生物等效性，评价受试制剂富马酸比索洛尔片（规格：5 mg）和参比制剂富马酸比索洛尔片（商品名：康忻®，规格：5 mg）在健康受试者中的安全性。

[Translation]

Bisoprolol fumarate tablets (specification: 5 mg) produced by Harbin Zhenbao Pharmaceutical Co., Ltd. was used as the test preparation, and bisoprolol fumarate tablets (trade name: Kangxin®; specification: 5 mg) certified by Merck Serono GmbH was used as the reference preparation. The bioequivalence of the test preparation and the reference preparation when administered under fasting and postprandial conditions was evaluated, and the safety of the test preparation bisoprolol fumarate tablets (specification: 5 mg) and the reference preparation bisoprolol fumarate tablets (trade name: Kangxin®, specification: 5 mg) in healthy subjects was evaluated.

Start Date23 Mar 2023

Sponsor / Collaborator

Haerbin Zhenbao Pharmacy Co. Ltd.

100 Clinical Results associated with HeiLongJiang ZBD Pharmaceutical Co., Ltd.

0 Patents (Medical) associated with HeiLongJiang ZBD Pharmaceutical Co., Ltd.

Literatures (Medical) associated with HeiLongJiang ZBD Pharmaceutical Co., Ltd.

01 Feb 2025·Journal of Ethnopharmacology

Lignans from Schisandra chinensis (Turcz.) Baill ameliorates cognitive impairment in Alzheimer's disease and alleviates ferroptosis by activating the Nrf2/FPN1 signaling pathway and regulating iron levels

Article

Author: Kuang, Hai-Xue ; Chen, Qing-Shan ; Zhao, Wei ; Yan, Jiu-Jiang ; Guan, Wei ; Liu, Yan ; Jiang, Yi-Kai ; Yang, Bing-You ; Hao, Zhi-Chao ; Wang, Si-Yi ; Xu, Shi-Qi ; Li, Meng-Meng ; Yao, Hong-Yan ; Yang, Rui ; Meng, Xin

ETHNOPHARMACOLOGICAL RELEVANCESchisandra chinensis (Turcz.) Baill (S. chinensis), first recorded in Shennong's Classic of the Materia Medica, is described as a "top grade medicine". As a traditional Chinese medicine of tonifying the kidneys and the brain, S. chinensis is widely used to treat diseases such as amnesia and dementia. Alzheimer's disease (AD) is a neurodegenerative disease, and ferroptosis is one of the essential causes of AD. Although previous studies have suggested that the lignans of S. chinensis (SCL) have neuroprotective effects, it is unclear whether SCL can alleviate AD pathology by inhibiting ferroptosis.AIM OF THE STUDYTo investigate the effect of SCL on AD caused by ferroptosis and its possible molecular mechanism.MATERIALS AND METHODSThis study was based on SAMR1/SAMP8 mouse models along with Erastin-induced HT22 cell lines to examine the influence of SCL on ferroptosis in AD. The S. chinensis was extracted via 75% EtOH-H₂O and identified by HPLC/UPLC-QTOF-MS. MWM assessed spatial learning, while HE staining, biochemical detection, IHC, and WB analyzed AD pathology and iron metabolism. Mitochondrial changes were evaluated by TEM, and confocal imaging post-SCL treatment analyzed ROS, MMP, and Fe²⁺ levels in HT22 cells. IF determined the expression levels and localization of Nrf2 and FPN1. CETSA was deployed to study the interaction between SCL and Nrf2.RESULTSTreatment with SCL mitigated cognitive dysfunction and reduced p-Tau as well as neuronal loss in AD model mice. Additionally, the administration of SCL alleviated oxidative stress and maintained relatively intact mitochondrial ridges and membranes, decreased TFR and DMT1 protein expression, and upregulated FTH1. Consistent with the in vivo results, SCL inhibited Erastin-induced ferroptosis in HT22 cells. SCL promoted Nrf2 nuclear translocation and upregulated FPN1, SLC7A11, and GPX4 protein expressions while decreasing FACL4. The improvement of ferroptosis by SCL was associated with the regulation of the Nrf2/FPN1 signaling pathway.CONCLUSIONThe novel discoveries of this study suggest that SCL can suppress ferroptosis in the brains of AD model mice and exerts a partial protective effect against Erastin-induced ferroptosis in HT22 cells, in which the Nrf2/FPN1 signaling pathway plays a crucial role.

06 Aug 2021·Organic LettersQ1 · CHEMISTRY

Rhodium-Catalyzed Regioselective Formal Hydroacylation of Vinyl Epoxides toward Esters Involving β-Carbon Cleavage

Q1 · CHEMISTRY

Article

Author: Li, Hong-Shuang ; Wang, Xiaodan ; Chang, Zhi-Xin ; Han, Junfen ; Zhang, Tongbo ; Gong, Fei-Yuan

Herein we disclose the first example of the formal hydroacylation reactions of vinyl epoxides with chelating aldehydes enabled by rhodium catalysis for the efficient construction of functionalized esters. Detailed investigations of the mechanistic pathway reveal that the presence of a 2-vinyl group is essential in contributing to the success of this regioselective reaction, which might proceed through β-carbon cleavage as the key procedure.

02 Jan 2021·Pharmaceutical Development and TechnologyQ4 · MEDICINE

Novel biomimetic nanostructured lipid carriers for cancer therapy: preparation, characterization, and in vitro/in vivo evaluation

Q4 · MEDICINE

Article

Author: Guo, Biru ; Cao, Lixin ; Zhou, Jianwen ; Sui, Xiaoyu ; Ma, Xiaoxing ; Han, Cuiyan ; Qian, Jiayi ; Zhu, Wenquan

Nanostructured lipid carriers (NLC) have become a research hotspot, wherein cancer-targeting effects are enhanced and side effects of chemotherapy are overcome. Usually, accelerated blood clearance (ABC) occurs after repeated injections, without changing the immunologic profile, despite PEGylation which prolongs the circulation function. To overcome these problems, we designed a red blood cell-membrane-coated NLC (RBCm-NLC), which was round-like, with a particle size of 60.33 ± 3.04 nm and a core-shell structure. Its stability was good, the drug paclitaxel (PTX) release from RBCm-PTX-NLC was less than 30% at pH7.4 and pH6.5, and the integrity of RBC membrane surface protein was maintained before and after preparation. Additionally, in vitro assays showed that, with the RBCm coating, the cellular uptake of the NLC by cancer cells was significantly enhanced. RBCm-NLC can avoid recognition by macrophage cells and prolong circulation time in vivo. In S180 tumor-bearing mice, the DiR-labeled RBCm-NLC group showed a stronger fluorescence signal and longer retention in tumor tissues, indicating a prompt tumor-targeting effect and extended blood circulation. Importantly, RBCm-PTX-NLC enhanced the antitumor effect and extended the survival period significantly in vivo. In summary, biomimetic NLC offered a novel strategy for drug delivery in cancer therapy.

100 Deals associated with HeiLongJiang ZBD Pharmaceutical Co., Ltd.

100 Translational Medicine associated with HeiLongJiang ZBD Pharmaceutical Co., Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 24 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Approval

Phase 1 Clinical

Approved

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

XueShuanTong Capsule	Brain Infarction More	Approved
FuFangQinlan	Common Cold More	Approved
HZB0071 ( Akt )	Neoplasms More	Phase 1
HZB1006 ( FGFRs x VEGFR )	Liver Cancer More	Phase 1
HNC-042 ( neuraminidase )	Influenza, Human More	Phase 1

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis